Periodic Reporting for period 1 - PMed (Enabling patient specific medicines using 3D printing in hospitals and pharmacies)
Reporting period: 2023-09-01 to 2024-08-31
Uniform drug treatments are not always the best option for treating some patient populations – including children and the elderly. The industry now has extensive knowledge on the benefits of personalized medicines that take the age, metabolic and genetic differences of patients into account. However, until now there has not been a practical manufacturing solution to put this knowledge into widescale use. CurifyLabs has created a technology called PharmaKit to make high quality personalized medicines available on site in the pharmacies through advanced automation technology inspired by 3D printing and bring industry level standards to mass customisation of medicines. In this project we will finalize a standard process for developing compatible formulations and quality control solutions for the PharmaKit technology. This will make PharmaKit highly scalable across different therapeutic areas.
Three new excipient premixes have been developed, with formulations ready for printing five new APIs, supporting expanded applications in pharmaceutical compounding.
Precision scale integration has been completed, ensuring highly accurate and 100% weight verification for all printed dosage forms.
The PharmaPrinter is now connected to Google Cloud, facilitating real-time data transfer for centralized monitoring, data analysis, and remote management of the printing process.
ISO 13485 Certification was awarded in June 2024 for the PharmaKit Technology Platform developed to enable automated, personalized medicine manufacturing.
Precision scale integration has been completed, ensuring highly accurate and 100% weight verification for all printed dosage forms.
The PharmaPrinter is now connected to Google Cloud, facilitating real-time data transfer for centralized monitoring, data analysis, and remote management of the printing process.
ISO 13485 Certification was awarded in June 2024 for the PharmaKit Technology Platform developed to enable automated, personalized medicine manufacturing.
The development of three new excipient premixes represents a leap beyond current industry standards, enabling enhanced stability and compatibility across multiple APIs with this type of technology platform. These innovations are not only tailored for regulatory alignment but also uniquely formulated for precise delivery of active ingredients, allowing for accurate and efficient printing of five new APIs. This forward-thinking approach places us at the forefront of compounding technology, extending possibilities for individualized therapy.
With precision-scale integration, we are setting a new benchmark in dosage accuracy. The PharmaPrinter’s 100% weight verification capabilities streamline production, minimize human error, and ensure each dose meets exact specifications. This degree of control over dosage integrity surpasses traditional compounding methods, offering a level of precision vital for patient safety and advancing pharmaceutical standards.
By connecting the PharmaPrinter to Google Cloud, we are pushing beyond the state of the art in data transparency and operational efficiency. This real-time cloud integration allows for centralized monitoring, remote management, and detailed data analysis, providing a level of oversight unprecedented in traditional compounding setups. This innovation not only improves accessibility for pharmacists and QC teams but also enhances adaptability and responsiveness within the manufacturing environment.
Achieving ISO 13485 Certification in June 2024 for the PharmaKit Technology Platform for Automated Manufacturing of Personalized Medicines underscores our commitment to leading the industry in quality and safety standards. This certification recognizes the PharmaKit’s alignment with international medical device standards and its potential to reshape personalized medicine manufacturing by automating precise, compliant, and adaptable production practices.
Each of these advancements moves us beyond current capabilities, positioning us at the leading edge of pharmaceutical technology and personalized medicine production.
With precision-scale integration, we are setting a new benchmark in dosage accuracy. The PharmaPrinter’s 100% weight verification capabilities streamline production, minimize human error, and ensure each dose meets exact specifications. This degree of control over dosage integrity surpasses traditional compounding methods, offering a level of precision vital for patient safety and advancing pharmaceutical standards.
By connecting the PharmaPrinter to Google Cloud, we are pushing beyond the state of the art in data transparency and operational efficiency. This real-time cloud integration allows for centralized monitoring, remote management, and detailed data analysis, providing a level of oversight unprecedented in traditional compounding setups. This innovation not only improves accessibility for pharmacists and QC teams but also enhances adaptability and responsiveness within the manufacturing environment.
Achieving ISO 13485 Certification in June 2024 for the PharmaKit Technology Platform for Automated Manufacturing of Personalized Medicines underscores our commitment to leading the industry in quality and safety standards. This certification recognizes the PharmaKit’s alignment with international medical device standards and its potential to reshape personalized medicine manufacturing by automating precise, compliant, and adaptable production practices.
Each of these advancements moves us beyond current capabilities, positioning us at the leading edge of pharmaceutical technology and personalized medicine production.